Hiroaki Akamatsu

Hiroaki Akamatsu

Auto-generated profile, based on publicly available information

Hiroaki Akamatsu

Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AOAkira Ono
Akira Ono
TTToshiaki Takahashi
Toshiaki Takahashi
KMKeita Mori
Keita Mori
HAHiroaki Akamatsu
Hiroaki Akamatsu
TSTakehito Shukuya
Takehito Shukuya
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
Serum CYFRA 21–1 is one of the most important serum markers in the diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma. However, it remains unknown whether pretreatment serum CYFRA 21–1 values (PCV) may also have prognostic implications in patients with advanced lung adenocarcinoma.

1 April 2014 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
HAHiroaki Akamatsu
Hiroaki Akamatsu
KKKyoichi Kaira
Kyoichi Kaira
HMHaruyasu Murakami
Haruyasu Murakami
MSMasakuni Serizawa
Masakuni Serizawa
YKYasuhiro Koh
Yasuhiro Koh
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
Objectives: Among patients with locally advanced lung adenocarcinoma, the frequency of epidermal growth factor receptor (EGFR) and KRAS mutations was unknown. In addition, it has not been fully evaluated about the role of these mutations treated with concurrent chemoradiotherapy (CCR). Methods: The clinical records of locally advanced lung adenocarcinoma patients treated with CCR at Shizuoka Cancer Center between September 2002 and December 2009 were reviewed. Results: Forty-four patients were eligible for this study. EGFR mutation was detected in 13 (29.5%) of 44 patients, and KRAS mutation was detected in 2 (6.5%) of 31 patients. Among EGFR mutation status known patients, overall response rate, median progression-free survival (PFS), and median survival time were 52.3%, 11.5 months, and 35.8 months, respectively. Overall response rate was significantly higher in EGFR mutant group than in EGFR wild-type group (76.9% vs. 41.9%, P=0.02), but this difference did not translate into a significant PFS benefit (9.6 vs. 13.2 mo, P=0.78). Locoregional relapse occured less frequently in patients with EGFR mutation than those with EGFR wild-type, but not significant (15.4% vs. 32.3%, P=0.46). Brain was the most frequent metastatic site of relapse in EGFR mutant group. Conclusions: Among locally advanced lung adenocarcinoma, EGFR mutation was detected in 29.5% and KRAS mutation was detected in 6.5%. We were not able to detect a difference in PFS or overall survival between EGFR mutant and wild-type patients treated with conventional CCR. Locoregional relapse was approximately half in the EGFR mutant group compared with the EGFR wild-type group; however, this finding did not reach statistical significance.

12 April 2013 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
HAHiroaki Akamatsu
Hiroaki Akamatsu
AIAkira Inoue
Akira Inoue
TMTetsuya Mitsudomi
Tetsuya Mitsudomi
KKKunihiko Kobayashi
Kunihiko Kobayashi
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
Interstitial lung disease associated with gefitinib is a critical adverse reaction. When geftinib was administered to EGFR-unknown patients, the interstitial lung disease incidence rate was approximately 3–4% in Japan, and usually occurs during the first 4 weeks of treatment. However, it has not been fully investigated in EGFR-mutated patients. We collected clinical records of participants of two Phase III trials (WJTOG 3405 and NEJ 002), which compared gefitinib with platinum doublet chemotherapy. All patients were EGFR mutated, chemo-naïve and had good performance status. A total of 402 patients were enrolled in this study. In the gefitinib arm, 10 (5.0%) of 201 patients developed interstitial lung disease, of whom five (2.5%) were Grade 3 or greater, with two deaths (1.0%). In contrast, only one patient developed interstitial lung disease (Grade 1) in the chemotherapy arm. With regard to gefitinib, smoking history was significantly associated with developing interstitial lung disease (odds ratio 0.18; 95% confidence interval: 0.05–0.74; P = 0.01). The cumulative incidence rate of interstitial lung disease was similar in the 0–4, 5–8 and 9–12 week time periods. However, between smokers and never-smokers, cumulative incidence rates in the first 4 weeks were significantly different (4.7% versus 0%, P = 0.03). Three of 10 patients developed interstitial lung disease after 8 weeks of gefitinib administration (days 135, 171 and 190, respectively). Among EGFR-mutated patients, the incidence of interstitial lung disease associated with gefitinib was not different from that in previous reports. Smoking history was associated with developing interstitial lung disease, and smokers had a higher incidence rate of interstitial lung disease in the first 4 weeks.

10 September 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AOAkira Ono
Akira Ono
TTToshiaki Takahashi
Toshiaki Takahashi
TOTakuma Oishi
Takuma Oishi
TSTakashi Sugino
Takashi Sugino
HAHiroaki Akamatsu
Hiroaki Akamatsu
NYNobuyuki Yamamoto
Nobuyuki Yamamoto

27 November 2010 in Japanese Journal of Radiology
Verified
Journal Article
Closed access
PDF file
HAHiroaki Akamatsu
Hiroaki Akamatsu
ATAsuka Tsuya
Asuka Tsuya
KKKyoichi Kaira
Kyoichi Kaira
YNYukiko Nakamura
Yukiko Nakamura
Tateaki NaitoTateaki Naito
Tateaki Naito
NYNobuyuki Yamamoto
Nobuyuki Yamamoto

21 January 2014 in Respiratory Investigation
Verified
Journal Article
Closed access
PDF file
TTTakaaki Tokito
Takaaki Tokito
TSTakehito Shukuya
Takehito Shukuya
HAHiroaki Akamatsu
Hiroaki Akamatsu
AOAkira Ono
Akira Ono
TTTetsuhiko Taira
Tetsuhiko Taira
NYNobuyuki Yamamoto
Nobuyuki Yamamoto